Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Lisinopril
All strengths: General benefit; same patient cost rules
Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Lisinopril (Type Z) · DIN 02525186 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Lisinopril (Type Z) · DIN 02525186
Manufacturer: Sanis Health Inc.; listing date 2022-10-31
Daily cost (source): $0.1347
Health Canada: Marketed since 2025-03-17 · brand LISINOPRIL (TYPE Z) · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL 5 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordLisinopril (Type Z): Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1347). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02525186)
Source record
DIN 02525186: Lisinopril (Type Z)
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800150; group id 333; item number 0748; lccId None; manufacturer id SAI
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1347; ministry $0.1347
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02525186
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101418
Interchangeable products
Apo-Lisinopril · DIN 02217481 · $0.1347
Auro-Lisinopril · DIN 02394472 · $0.1347
Co Lisinopril · DIN 02271443 · $0.1347
Jamp-Lisinopril · DIN 02361531 · $0.1347
Lisinopril · DIN 02386232 · $0.1347
Lisinopril Tablets · DIN 02554488 · $0.1347
Ran-Lisinopril · DIN 02294230 · $0.1347
Sandoz Lisinopril · DIN 02289199 · $0.1347
Teva-Lisinopril (Type Z) · DIN 02285118 · $0.1347
Zestril · DIN 02049333 · $0.1347
Shortage status: resolved shortage (ended March 3, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02525186
Shortage record checked October 6, 2026
Teva-Lisinopril (Type Z) · DIN 02285118 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Lisinopril (Type Z) · DIN 02285118
Manufacturer: Teva Canada Limited; listing date 2007-12-19
Daily cost (source): $0.1347
Health Canada: Marketed since 2010-12-09 · brand TEVA-LISINOPRIL (TYPE Z) · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL 5 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Lisinopril (Type Z): Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1347). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02285118)
Source record
DIN 02285118: Teva-Lisinopril (Type Z)
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800150; group id 333; item number 0748; lccId None; manufacturer id TEV
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1347; ministry $0.1347
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02285118
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77062
Interchangeable products
Apo-Lisinopril · DIN 02217481 · $0.1347
Auro-Lisinopril · DIN 02394472 · $0.1347
Co Lisinopril · DIN 02271443 · $0.1347
Jamp-Lisinopril · DIN 02361531 · $0.1347
Lisinopril · DIN 02386232 · $0.1347
Lisinopril (Type Z) · DIN 02525186 · $0.1347
Lisinopril Tablets · DIN 02554488 · $0.1347
Ran-Lisinopril · DIN 02294230 · $0.1347
Sandoz Lisinopril · DIN 02289199 · $0.1347
Zestril · DIN 02049333 · $0.1347
Shortage status: resolved shortage (ended November 25, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02285118
Shortage record checked October 6, 2026
Lisinopril (Type Z) · DIN 02525194 · 10 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Lisinopril (Type Z) · DIN 02525194
Manufacturer: Sanis Health Inc.; listing date 2022-10-31
Daily cost (source): $0.1619
Health Canada: Marketed since 2025-03-17 · brand LISINOPRIL (TYPE Z) · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL 10 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordLisinopril (Type Z): Formulary list price $0.16 per unit (the source does not state the unit; exact figure $0.1619). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02525194)
Source record
DIN 02525194: Lisinopril (Type Z)
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800151; group id 333; item number 0749; lccId None; manufacturer id SAI
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1619; ministry $0.1619
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02525194
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101419
Interchangeable products
Apo-Lisinopril · DIN 02217503 · $0.1619
Auro-Lisinopril · DIN 02394480 · $0.1619
Co Lisinopril · DIN 02271451 · $0.1619
Jamp-Lisinopril · DIN 02361558 · $0.1619
Lisinopril · DIN 02386240 · $0.1619
Lisinopril Tablets · DIN 02554496 · $0.1619
Ran-Lisinopril · DIN 02294249 · $0.1619
Sandoz Lisinopril · DIN 02289202 · $0.1619
Teva-Lisinopril (Type Z) · DIN 02285126 · $0.1619
Zestril · DIN 02049376 · $0.1619
Shortage status: resolved shortage (ended March 3, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02525194
Shortage record checked October 6, 2026
Teva-Lisinopril (Type Z) · DIN 02285126 · 10 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Lisinopril (Type Z) · DIN 02285126
Manufacturer: Teva Canada Limited; listing date 2007-12-19
Daily cost (source): $0.1619
Health Canada: Marketed since 2010-12-09 · brand TEVA-LISINOPRIL (TYPE Z) · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL 10 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Lisinopril (Type Z): Formulary list price $0.16 per unit (the source does not state the unit; exact figure $0.1619). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02285126)
Source record
DIN 02285126: Teva-Lisinopril (Type Z)
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800151; group id 333; item number 0749; lccId None; manufacturer id TEV
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1619; ministry $0.1619
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02285126
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77063
Interchangeable products
Apo-Lisinopril · DIN 02217503 · $0.1619
Auro-Lisinopril · DIN 02394480 · $0.1619
Co Lisinopril · DIN 02271451 · $0.1619
Jamp-Lisinopril · DIN 02361558 · $0.1619
Lisinopril · DIN 02386240 · $0.1619
Lisinopril (Type Z) · DIN 02525194 · $0.1619
Lisinopril Tablets · DIN 02554496 · $0.1619
Ran-Lisinopril · DIN 02294249 · $0.1619
Sandoz Lisinopril · DIN 02289202 · $0.1619
Zestril · DIN 02049376 · $0.1619
Shortage status: resolved shortage (ended August 7, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02285126
Shortage record checked October 6, 2026
Lisinopril (Type Z) · DIN 02525208 · 20 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Lisinopril (Type Z) · DIN 02525208
Manufacturer: Sanis Health Inc.; listing date 2022-10-31
Daily cost (source): $0.1945
Health Canada: Marketed since 2025-03-17 · brand LISINOPRIL (TYPE Z) · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL 20 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordLisinopril (Type Z): Formulary list price $0.19 per unit (the source does not state the unit; exact figure $0.1945). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02525208)
Source record
DIN 02525208: Lisinopril (Type Z)
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800152; group id 333; item number 0750; lccId None; manufacturer id SAI
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1945; ministry $0.1945
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02525208
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101420
Interchangeable products
Apo-Lisinopril · DIN 02217511 · $0.1945
Auro-Lisinopril · DIN 02394499 · $0.1945
Co Lisinopril · DIN 02271478 · $0.1945
Jamp-Lisinopril · DIN 02361566 · $0.1945
Lisinopril · DIN 02386259 · $0.1945
Lisinopril Tablets · DIN 02554518 · $0.1945
Ran-Lisinopril · DIN 02294257 · $0.1945
Sandoz Lisinopril · DIN 02289229 · $0.1945
Teva-Lisinopril (Type Z) · DIN 02285134 · $0.1945
Zestril · DIN 02049384 · $0.1945
Shortage status: resolved shortage (ended March 31, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02525208
Shortage record checked October 6, 2026
Teva-Lisinopril (Type Z) · DIN 02285134 · 20 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Lisinopril (Type Z) · DIN 02285134
Manufacturer: Teva Canada Limited; listing date 2007-12-19
Daily cost (source): $0.1945
Health Canada: Marketed since 2010-12-09 · brand TEVA-LISINOPRIL (TYPE Z) · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL 20 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Lisinopril (Type Z): Formulary list price $0.19 per unit (the source does not state the unit; exact figure $0.1945). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02285134)
Source record
DIN 02285134: Teva-Lisinopril (Type Z)
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800152; group id 333; item number 0750; lccId None; manufacturer id TEV
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1945; ministry $0.1945
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02285134
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77064
Interchangeable products
Apo-Lisinopril · DIN 02217511 · $0.1945
Auro-Lisinopril · DIN 02394499 · $0.1945
Co Lisinopril · DIN 02271478 · $0.1945
Jamp-Lisinopril · DIN 02361566 · $0.1945
Lisinopril · DIN 02386259 · $0.1945
Lisinopril (Type Z) · DIN 02525208 · $0.1945
Lisinopril Tablets · DIN 02554518 · $0.1945
Ran-Lisinopril · DIN 02294257 · $0.1945
Sandoz Lisinopril · DIN 02289229 · $0.1945
Zestril · DIN 02049384 · $0.1945
Shortage status: resolved shortage (ended May 28, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02285134
Shortage record checked October 6, 2026
Auro-Lisinopril · DIN 02394472 · 5 mg · tablet
General benefitMarketed · checked November 19, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Lisinopril · DIN 02394472
Manufacturer: Auro Pharma Inc.; listing date 2013-04-30
Daily cost (source): $0.1347
Health Canada: Marketed since 2013-02-12 · brand AURO-LISINOPRIL · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL (LISINOPRIL DIHYDRATE) 5 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Lisinopril: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1347). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02394472)
Source record
DIN 02394472: Auro-Lisinopril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800150; group id 333; item number 0748; lccId None; manufacturer id AUR
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1347; ministry $0.1347
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02394472
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87963
Interchangeable products
Apo-Lisinopril · DIN 02217481 · $0.1347
Co Lisinopril · DIN 02271443 · $0.1347
Jamp-Lisinopril · DIN 02361531 · $0.1347
Lisinopril · DIN 02386232 · $0.1347
Lisinopril (Type Z) · DIN 02525186 · $0.1347
Lisinopril Tablets · DIN 02554488 · $0.1347
Ran-Lisinopril · DIN 02294230 · $0.1347
Sandoz Lisinopril · DIN 02289199 · $0.1347
Teva-Lisinopril (Type Z) · DIN 02285118 · $0.1347
Zestril · DIN 02049333 · $0.1347
Shortage status: resolved shortage (ended January 7, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02394472
Shortage record checked October 6, 2026
Lisinopril Tablets · DIN 02554488 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Lisinopril Tablets · DIN 02554488
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2026-01-30
Daily cost (source): $0.1347
Health Canada: Marketed since 2025-12-29 · brand LISINOPRIL TABLETS · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL (LISINOPRIL DIHYDRATE) 5 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordLisinopril Tablets: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1347). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02554488)
Source record
DIN 02554488: Lisinopril Tablets
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800150; group id 333; item number 0748; lccId None; manufacturer id SIV
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1347; ministry $0.1347
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02554488
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104333
Interchangeable products
Apo-Lisinopril · DIN 02217481 · $0.1347
Auro-Lisinopril · DIN 02394472 · $0.1347
Co Lisinopril · DIN 02271443 · $0.1347
Jamp-Lisinopril · DIN 02361531 · $0.1347
Lisinopril · DIN 02386232 · $0.1347
Lisinopril (Type Z) · DIN 02525186 · $0.1347
Ran-Lisinopril · DIN 02294230 · $0.1347
Sandoz Lisinopril · DIN 02289199 · $0.1347
Teva-Lisinopril (Type Z) · DIN 02285118 · $0.1347
Zestril · DIN 02049333 · $0.1347
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02554488
Shortage record checked October 6, 2026
Zestril · DIN 02049333 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Savings card: innoviCares lists Zestril (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up.
(innovicares.ca ↗)Savings card: RxHelp ONE lists ZESTRIL (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use)
(rxhelp.ca, September 10, 2026 ↗)1 brand, same coverage
Zestril · DIN 02049333
Manufacturer: AstraZeneca; listing date 1996-10-01
Daily cost (source): $0.5770
Health Canada: Marketed since 2022-02-28 · brand ZESTRIL · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL 5 MG · company Searchlight pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02049333)
Source record
DIN 02049333: Zestril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800150; group id 333; item number 0748; lccId None; manufacturer id AZC
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.5770; ministry $0.1347
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02049333
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17126
Interchangeable products
Apo-Lisinopril · DIN 02217481 · $0.1347
Auro-Lisinopril · DIN 02394472 · $0.1347
Co Lisinopril · DIN 02271443 · $0.1347
Jamp-Lisinopril · DIN 02361531 · $0.1347
Lisinopril · DIN 02386232 · $0.1347
Lisinopril (Type Z) · DIN 02525186 · $0.1347
Lisinopril Tablets · DIN 02554488 · $0.1347
Ran-Lisinopril · DIN 02294230 · $0.1347
Sandoz Lisinopril · DIN 02289199 · $0.1347
Teva-Lisinopril (Type Z) · DIN 02285118 · $0.1347
Shortage status: resolved shortage (ended January 15, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02049333
Shortage record checked October 6, 2026
Auro-Lisinopril · DIN 02394480 · 10 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Lisinopril · DIN 02394480
Manufacturer: Auro Pharma Inc.; listing date 2013-04-30
Daily cost (source): $0.1619
Health Canada: Marketed since 2013-02-12 · brand AURO-LISINOPRIL · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL (LISINOPRIL DIHYDRATE) 10 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Lisinopril: Formulary list price $0.16 per unit (the source does not state the unit; exact figure $0.1619). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02394480)
Source record
DIN 02394480: Auro-Lisinopril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800151; group id 333; item number 0749; lccId None; manufacturer id AUR
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1619; ministry $0.1619
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02394480
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87964
Interchangeable products
Apo-Lisinopril · DIN 02217503 · $0.1619
Co Lisinopril · DIN 02271451 · $0.1619
Jamp-Lisinopril · DIN 02361558 · $0.1619
Lisinopril · DIN 02386240 · $0.1619
Lisinopril (Type Z) · DIN 02525194 · $0.1619
Lisinopril Tablets · DIN 02554496 · $0.1619
Ran-Lisinopril · DIN 02294249 · $0.1619
Sandoz Lisinopril · DIN 02289202 · $0.1619
Teva-Lisinopril (Type Z) · DIN 02285126 · $0.1619
Zestril · DIN 02049376 · $0.1619
Shortage status: resolved shortage (ended March 27, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02394480
Shortage record checked October 6, 2026
Lisinopril Tablets · DIN 02554496 · 10 mg · tablet
General benefitMarketed · checked November 19, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Lisinopril Tablets · DIN 02554496
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2026-01-30
Daily cost (source): $0.1619
Health Canada: Marketed since 2025-12-29 · brand LISINOPRIL TABLETS · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL (LISINOPRIL DIHYDRATE) 10 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordLisinopril Tablets: Formulary list price $0.16 per unit (the source does not state the unit; exact figure $0.1619). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02554496)
Source record
DIN 02554496: Lisinopril Tablets
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800151; group id 333; item number 0749; lccId None; manufacturer id SIV
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1619; ministry $0.1619
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02554496
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104334
Interchangeable products
Apo-Lisinopril · DIN 02217503 · $0.1619
Auro-Lisinopril · DIN 02394480 · $0.1619
Co Lisinopril · DIN 02271451 · $0.1619
Jamp-Lisinopril · DIN 02361558 · $0.1619
Lisinopril · DIN 02386240 · $0.1619
Lisinopril (Type Z) · DIN 02525194 · $0.1619
Ran-Lisinopril · DIN 02294249 · $0.1619
Sandoz Lisinopril · DIN 02289202 · $0.1619
Teva-Lisinopril (Type Z) · DIN 02285126 · $0.1619
Zestril · DIN 02049376 · $0.1619
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02554496
Shortage record checked October 6, 2026
Zestril · DIN 02049376 · 10 mg · tablet
General benefitMarketed · checked November 19, 2026
Write on scriptno code needed
Savings card: innoviCares lists Zestril (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up.
(innovicares.ca ↗)Savings card: RxHelp ONE lists ZESTRIL (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use)
(rxhelp.ca, September 10, 2026 ↗)1 brand, same coverage
Zestril · DIN 02049376
Manufacturer: AstraZeneca; listing date 1996-10-01
Daily cost (source): $0.6935
Health Canada: Marketed since 2022-02-28 · brand ZESTRIL · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL 10 MG · company Searchlight pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02049376)
Source record
DIN 02049376: Zestril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800151; group id 333; item number 0749; lccId None; manufacturer id AZC
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.6935; ministry $0.1619
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02049376
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17215
Interchangeable products
Apo-Lisinopril · DIN 02217503 · $0.1619
Auro-Lisinopril · DIN 02394480 · $0.1619
Co Lisinopril · DIN 02271451 · $0.1619
Jamp-Lisinopril · DIN 02361558 · $0.1619
Lisinopril · DIN 02386240 · $0.1619
Lisinopril (Type Z) · DIN 02525194 · $0.1619
Lisinopril Tablets · DIN 02554496 · $0.1619
Ran-Lisinopril · DIN 02294249 · $0.1619
Sandoz Lisinopril · DIN 02289202 · $0.1619
Teva-Lisinopril (Type Z) · DIN 02285126 · $0.1619
Shortage status: resolved shortage (ended December 31, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02049376
Shortage record checked October 6, 2026
Auro-Lisinopril · DIN 02394499 · 20 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Lisinopril · DIN 02394499
Manufacturer: Auro Pharma Inc.; listing date 2013-04-30
Daily cost (source): $0.1945
Health Canada: Marketed since 2013-02-12 · brand AURO-LISINOPRIL · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL (LISINOPRIL DIHYDRATE) 20 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Lisinopril: Formulary list price $0.19 per unit (the source does not state the unit; exact figure $0.1945). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02394499)
Source record
DIN 02394499: Auro-Lisinopril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800152; group id 333; item number 0750; lccId None; manufacturer id AUR
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1945; ministry $0.1945
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02394499
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87965
Interchangeable products
Apo-Lisinopril · DIN 02217511 · $0.1945
Co Lisinopril · DIN 02271478 · $0.1945
Jamp-Lisinopril · DIN 02361566 · $0.1945
Lisinopril · DIN 02386259 · $0.1945
Lisinopril (Type Z) · DIN 02525208 · $0.1945
Lisinopril Tablets · DIN 02554518 · $0.1945
Ran-Lisinopril · DIN 02294257 · $0.1945
Sandoz Lisinopril · DIN 02289229 · $0.1945
Teva-Lisinopril (Type Z) · DIN 02285134 · $0.1945
Zestril · DIN 02049384 · $0.1945
Shortage status: resolved shortage (ended January 7, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02394499
Shortage record checked October 6, 2026
Jamp-Lisinopril · DIN 02361566 · 20 mg · tablet
General benefitMarketed · checked November 19, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Lisinopril · DIN 02361566
Manufacturer: Jamp Pharma Corporation; listing date 2012-01-19
Daily cost (source): $0.1945
Health Canada: Marketed since 2026-09-30 · brand JAMP-LISINOPRIL · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL (LISINOPRIL DIHYDRATE) 20 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp-Lisinopril: Formulary list price $0.19 per unit (the source does not state the unit; exact figure $0.1945). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada); extract: Dormant October 31, 2025; live record preferred: Marketed September 30, 2026 (checked November 19, 2026) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02361566)
Source record
DIN 02361566: Jamp-Lisinopril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800152; group id 333; item number 0750; lccId None; manufacturer id JPC
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1945; ministry $0.1945
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02361566
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada); extract: Dormant October 31, 2025; live record preferred: Marketed September 30, 2026 (checked November 19, 2026) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84663
Interchangeable products
Apo-Lisinopril · DIN 02217511 · $0.1945
Auro-Lisinopril · DIN 02394499 · $0.1945
Co Lisinopril · DIN 02271478 · $0.1945
Lisinopril · DIN 02386259 · $0.1945
Lisinopril (Type Z) · DIN 02525208 · $0.1945
Lisinopril Tablets · DIN 02554518 · $0.1945
Ran-Lisinopril · DIN 02294257 · $0.1945
Sandoz Lisinopril · DIN 02289229 · $0.1945
Teva-Lisinopril (Type Z) · DIN 02285134 · $0.1945
Zestril · DIN 02049384 · $0.1945
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02361566
Shortage record checked October 6, 2026
Lisinopril Tablets · DIN 02554518 · 20 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Lisinopril Tablets · DIN 02554518
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2026-01-30
Daily cost (source): $0.1945
Health Canada: Marketed since 2025-12-29 · brand LISINOPRIL TABLETS · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL (LISINOPRIL DIHYDRATE) 20 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordLisinopril Tablets: Formulary list price $0.19 per unit (the source does not state the unit; exact figure $0.1945). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02554518)
Source record
DIN 02554518: Lisinopril Tablets
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800152; group id 333; item number 0750; lccId None; manufacturer id SIV
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1945; ministry $0.1945
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02554518
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104335
Interchangeable products
Apo-Lisinopril · DIN 02217511 · $0.1945
Auro-Lisinopril · DIN 02394499 · $0.1945
Co Lisinopril · DIN 02271478 · $0.1945
Jamp-Lisinopril · DIN 02361566 · $0.1945
Lisinopril · DIN 02386259 · $0.1945
Lisinopril (Type Z) · DIN 02525208 · $0.1945
Ran-Lisinopril · DIN 02294257 · $0.1945
Sandoz Lisinopril · DIN 02289229 · $0.1945
Teva-Lisinopril (Type Z) · DIN 02285134 · $0.1945
Zestril · DIN 02049384 · $0.1945
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02554518
Shortage record checked October 6, 2026
Zestril · DIN 02049384 · 20 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Savings card: innoviCares lists Zestril (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up.
(innovicares.ca ↗)Savings card: RxHelp ONE lists ZESTRIL (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use)
(rxhelp.ca, September 10, 2026 ↗)1 brand, same coverage
Zestril · DIN 02049384
Manufacturer: AstraZeneca; listing date 1996-10-01
Daily cost (source): $0.8330
Health Canada: Marketed since 2022-02-28 · brand ZESTRIL · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL 20 MG · company Searchlight pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02049384)
Source record
DIN 02049384: Zestril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800152; group id 333; item number 0750; lccId None; manufacturer id AZC
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.8330; ministry $0.1945
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02049384
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17123
Interchangeable products
Apo-Lisinopril · DIN 02217511 · $0.1945
Auro-Lisinopril · DIN 02394499 · $0.1945
Co Lisinopril · DIN 02271478 · $0.1945
Jamp-Lisinopril · DIN 02361566 · $0.1945
Lisinopril · DIN 02386259 · $0.1945
Lisinopril (Type Z) · DIN 02525208 · $0.1945
Lisinopril Tablets · DIN 02554518 · $0.1945
Ran-Lisinopril · DIN 02294257 · $0.1945
Sandoz Lisinopril · DIN 02289229 · $0.1945
Teva-Lisinopril (Type Z) · DIN 02285134 · $0.1945
Shortage status: resolved shortage (ended November 6, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02049384
Shortage record checked October 6, 2026
Apo-Lisinopril · DIN 02217481 · 5 mg · tablet
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Lisinopril · DIN 02217481
Manufacturer: Apotex Inc.; listing date 1997-08-28
Daily cost (source): $0.1347
Health Canada: Dormant since 2026-02-04 · brand APO-LISINOPRIL · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL 5 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Lisinopril: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1347). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02217481)
Source record
DIN 02217481: Apo-Lisinopril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800150; group id 333; item number 0748; lccId None; manufacturer id APX
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1347; ministry $0.1347
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02217481
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43221
Interchangeable products
Auro-Lisinopril · DIN 02394472 · $0.1347
Co Lisinopril · DIN 02271443 · $0.1347
Jamp-Lisinopril · DIN 02361531 · $0.1347
Lisinopril · DIN 02386232 · $0.1347
Lisinopril (Type Z) · DIN 02525186 · $0.1347
Lisinopril Tablets · DIN 02554488 · $0.1347
Ran-Lisinopril · DIN 02294230 · $0.1347
Sandoz Lisinopril · DIN 02289199 · $0.1347
Teva-Lisinopril (Type Z) · DIN 02285118 · $0.1347
Zestril · DIN 02049333 · $0.1347
Shortage status: active shortage (reported January 28, 2025, last updated January 30, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02217481
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since February 4, 2026 — choose a marketed DIN from the same-category list.
Jamp-Lisinopril · DIN 02361531 · 5 mg · tablet
General benefitDormant since October 31, 2025 · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Lisinopril · DIN 02361531
Manufacturer: Jamp Pharma Corporation; listing date 2012-01-19
Daily cost (source): $0.1347
Health Canada: Dormant since 2025-10-31 · brand JAMP-LISINOPRIL · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL (LISINOPRIL DIHYDRATE) 5 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp-Lisinopril: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1347). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02361531)
Source record
DIN 02361531: Jamp-Lisinopril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800150; group id 333; item number 0748; lccId None; manufacturer id JPC
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1347; ministry $0.1347
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02361531
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84661
Interchangeable products
Apo-Lisinopril · DIN 02217481 · $0.1347
Auro-Lisinopril · DIN 02394472 · $0.1347
Co Lisinopril · DIN 02271443 · $0.1347
Lisinopril · DIN 02386232 · $0.1347
Lisinopril (Type Z) · DIN 02525186 · $0.1347
Lisinopril Tablets · DIN 02554488 · $0.1347
Ran-Lisinopril · DIN 02294230 · $0.1347
Sandoz Lisinopril · DIN 02289199 · $0.1347
Teva-Lisinopril (Type Z) · DIN 02285118 · $0.1347
Zestril · DIN 02049333 · $0.1347
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02361531
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since October 31, 2025 — choose a marketed DIN from the same-category list.
Lisinopril · DIN 02386232 · 5 mg · tablet
General benefitDormant since July 3, 2026 · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Lisinopril · DIN 02386232
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-10-30
Daily cost (source): $0.1347
Health Canada: Dormant since 2026-07-03 · brand LISINOPRIL · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL 5 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordLisinopril: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1347). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02386232)
Source record
DIN 02386232: Lisinopril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800150; group id 333; item number 0748; lccId None; manufacturer id SIV
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1347; ministry $0.1347
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02386232
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87181
Interchangeable products
Apo-Lisinopril · DIN 02217481 · $0.1347
Auro-Lisinopril · DIN 02394472 · $0.1347
Co Lisinopril · DIN 02271443 · $0.1347
Jamp-Lisinopril · DIN 02361531 · $0.1347
Lisinopril (Type Z) · DIN 02525186 · $0.1347
Lisinopril Tablets · DIN 02554488 · $0.1347
Ran-Lisinopril · DIN 02294230 · $0.1347
Sandoz Lisinopril · DIN 02289199 · $0.1347
Teva-Lisinopril (Type Z) · DIN 02285118 · $0.1347
Zestril · DIN 02049333 · $0.1347
Shortage status: active shortage (reported March 21, 2025, estimated to end December 1, 2026, last updated July 2, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02386232
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since July 3, 2026 — choose a marketed DIN from the same-category list.
Ran-Lisinopril · DIN 02294230 · 5 mg · tablet
General benefitDormant since May 31, 2024 · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ran-Lisinopril · DIN 02294230
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2007-12-19
Daily cost (source): $0.1347
Health Canada: Dormant since 2024-05-31 · brand TARO-LISINOPRIL · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL (LISINOPRIL DIHYDRATE) 5 MG · company Sun pharma canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordRan-Lisinopril: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1347). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02294230)
Source record
DIN 02294230: Ran-Lisinopril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800150; group id 333; item number 0748; lccId None; manufacturer id RAN
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1347; ministry $0.1347
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02294230
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77958
Interchangeable products
Apo-Lisinopril · DIN 02217481 · $0.1347
Auro-Lisinopril · DIN 02394472 · $0.1347
Co Lisinopril · DIN 02271443 · $0.1347
Jamp-Lisinopril · DIN 02361531 · $0.1347
Lisinopril · DIN 02386232 · $0.1347
Lisinopril (Type Z) · DIN 02525186 · $0.1347
Lisinopril Tablets · DIN 02554488 · $0.1347
Sandoz Lisinopril · DIN 02289199 · $0.1347
Teva-Lisinopril (Type Z) · DIN 02285118 · $0.1347
Zestril · DIN 02049333 · $0.1347
Shortage status: resolved shortage (ended November 25, 2021); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02294230
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since May 31, 2024 — choose a marketed DIN from the same-category list.
Apo-Lisinopril · DIN 02217503 · 10 mg · tablet
General benefitDormant since December 9, 2024 · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Lisinopril · DIN 02217503
Manufacturer: Apotex Inc.; listing date 2001-06-07
Daily cost (source): $0.1619
Health Canada: Dormant since 2024-12-09 · brand APO-LISINOPRIL · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL 10 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Lisinopril: Formulary list price $0.16 per unit (the source does not state the unit; exact figure $0.1619). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02217503)
Source record
DIN 02217503: Apo-Lisinopril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800151; group id 333; item number 0749; lccId None; manufacturer id APX
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1619; ministry $0.1619
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02217503
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43222
Interchangeable products
Auro-Lisinopril · DIN 02394480 · $0.1619
Co Lisinopril · DIN 02271451 · $0.1619
Jamp-Lisinopril · DIN 02361558 · $0.1619
Lisinopril · DIN 02386240 · $0.1619
Lisinopril (Type Z) · DIN 02525194 · $0.1619
Lisinopril Tablets · DIN 02554496 · $0.1619
Ran-Lisinopril · DIN 02294249 · $0.1619
Sandoz Lisinopril · DIN 02289202 · $0.1619
Teva-Lisinopril (Type Z) · DIN 02285126 · $0.1619
Zestril · DIN 02049376 · $0.1619
Shortage status: active shortage (reported December 12, 2023, last updated April 5, 2024) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02217503
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since December 9, 2024 — choose a marketed DIN from the same-category list.
Jamp-Lisinopril · DIN 02361558 · 10 mg · tablet
General benefitDormant since October 31, 2025 · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Lisinopril · DIN 02361558
Manufacturer: Jamp Pharma Corporation; listing date 2012-01-19
Daily cost (source): $0.1619
Health Canada: Dormant since 2025-10-31 · brand JAMP-LISINOPRIL · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL (LISINOPRIL DIHYDRATE) 10 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp-Lisinopril: Formulary list price $0.16 per unit (the source does not state the unit; exact figure $0.1619). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02361558)
Source record
DIN 02361558: Jamp-Lisinopril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800151; group id 333; item number 0749; lccId None; manufacturer id JPC
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1619; ministry $0.1619
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02361558
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84662
Interchangeable products
Apo-Lisinopril · DIN 02217503 · $0.1619
Auro-Lisinopril · DIN 02394480 · $0.1619
Co Lisinopril · DIN 02271451 · $0.1619
Lisinopril · DIN 02386240 · $0.1619
Lisinopril (Type Z) · DIN 02525194 · $0.1619
Lisinopril Tablets · DIN 02554496 · $0.1619
Ran-Lisinopril · DIN 02294249 · $0.1619
Sandoz Lisinopril · DIN 02289202 · $0.1619
Teva-Lisinopril (Type Z) · DIN 02285126 · $0.1619
Zestril · DIN 02049376 · $0.1619
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02361558
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since October 31, 2025 — choose a marketed DIN from the same-category list.
Lisinopril · DIN 02386240 · 10 mg · tablet
General benefitDormant since July 3, 2026 · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Lisinopril · DIN 02386240
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-10-30
Daily cost (source): $0.1619
Health Canada: Dormant since 2026-07-03 · brand LISINOPRIL · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL 10 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordLisinopril: Formulary list price $0.16 per unit (the source does not state the unit; exact figure $0.1619). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02386240)
Source record
DIN 02386240: Lisinopril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800151; group id 333; item number 0749; lccId None; manufacturer id SIV
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1619; ministry $0.1619
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02386240
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87182
Interchangeable products
Apo-Lisinopril · DIN 02217503 · $0.1619
Auro-Lisinopril · DIN 02394480 · $0.1619
Co Lisinopril · DIN 02271451 · $0.1619
Jamp-Lisinopril · DIN 02361558 · $0.1619
Lisinopril (Type Z) · DIN 02525194 · $0.1619
Lisinopril Tablets · DIN 02554496 · $0.1619
Ran-Lisinopril · DIN 02294249 · $0.1619
Sandoz Lisinopril · DIN 02289202 · $0.1619
Teva-Lisinopril (Type Z) · DIN 02285126 · $0.1619
Zestril · DIN 02049376 · $0.1619
Shortage status: active shortage (reported August 10, 2024, estimated to end December 1, 2026, last updated July 2, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02386240
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since July 3, 2026 — choose a marketed DIN from the same-category list.
Ran-Lisinopril · DIN 02294249 · 10 mg · tablet
General benefitDormant since May 31, 2024 · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ran-Lisinopril · DIN 02294249
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2007-12-19
Daily cost (source): $0.1619
Health Canada: Dormant since 2024-05-31 · brand TARO-LISINOPRIL · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL (LISINOPRIL DIHYDRATE) 10 MG · company Sun pharma canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordRan-Lisinopril: Formulary list price $0.16 per unit (the source does not state the unit; exact figure $0.1619). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02294249)
Source record
DIN 02294249: Ran-Lisinopril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800151; group id 333; item number 0749; lccId None; manufacturer id RAN
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1619; ministry $0.1619
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02294249
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77959
Interchangeable products
Apo-Lisinopril · DIN 02217503 · $0.1619
Auro-Lisinopril · DIN 02394480 · $0.1619
Co Lisinopril · DIN 02271451 · $0.1619
Jamp-Lisinopril · DIN 02361558 · $0.1619
Lisinopril · DIN 02386240 · $0.1619
Lisinopril (Type Z) · DIN 02525194 · $0.1619
Lisinopril Tablets · DIN 02554496 · $0.1619
Sandoz Lisinopril · DIN 02289202 · $0.1619
Teva-Lisinopril (Type Z) · DIN 02285126 · $0.1619
Zestril · DIN 02049376 · $0.1619
Shortage status: resolved shortage (ended March 19, 2021); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02294249
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since May 31, 2024 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (C09AA): coverage varies; not interchangeable
- Benazepril (Lotensin): general benefit, not a benefit
- Captopril (Noyada): general benefit, limited Use 707, 723, not a benefit
- Cilazapril (Inhibace): general benefit, not a benefit
- Enalapril (Vasotec): general benefit, not a benefit
- Fosinopril (Monopril): general benefit, not a benefit
- Perindopril erbumine (Coversyl): general benefit
3 more in the class list below
Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered
Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Public program routes: ODB 65 and over
Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE
Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL
24:08 Hypotensive Drugs (For Diuretics See 40:28)
· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab
· 14 products ·
Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab
· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab
· 52 products · Listed, not a benefit (1), General benefit (51) · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab
· 12 products · Listed, not a benefit (2), General benefit (10) · strengths: 10mg, 20mg · Tab
· 48 products · General benefit · strengths: 2mg, 4mg, 8mg · Tab
· 12 products · Listed, not a benefit (4), General benefit (8) · strengths: 5mg, 10mg, 20mg, 40mg · Tab
· 67 products · General benefit (57), Listed, not a benefit (4), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 1.25mg, 2.5mg, 5mg, 10mg, 15mg · Cap
· 26 products · Off-Formulary Interchangeable, not an ODB benefit (4), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), General benefit (18), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (3) · strengths: 0.5mg, 1mg, 2mg, 4mg · Cap
· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab
· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab
· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:08
and 35 more
Full class listing
Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors
Same formulary class, not same indication: class membership alone does not establish equivalent uses.